BMEA Latest Headlines

Piper Sandler Sticks to Their Buy Rating for Biomea Fusion (BMEA)

at www.tipranks.com (Wed, 11-Nov 8:36 AM)

Biomea’s Advancing Diabetes Pipeline and Obesity Potential Support Buy; $4 Price Target Maintained

at www.tipranks.com (Wed, 11-Nov 6:55 AM)

Biomea Fusion: Unchanged $7 Price Target as Icovamenib Catalysts and GLP-1 Upside Drive Buy Case Despite Funding Risk

at www.tipranks.com (Wed, 11-Nov 5:35 AM)

Biomea Fusion GAAP EPS of -$0.09 beats by $0.11

at seekingalpha.com (Tue, 10-Nov 4:57 PM)

Biomea Fusion Reaches Enrollment Milestone in Key Phase II Diabetes Trial—What the COVALENT-211 Update Means for Insulin-Deficient T2D Patients

Market Chameleon (Tue, 25-Aug 11:08 AM)

Biomea Fusion Hits Enrollment Milestone for Icovamenib Phase II Trial in Insulin-Deficient Type 2 Diabetes

Market Chameleon (Mon, 24-Aug 10:30 AM)